Novel Biomarkers. Novel Approach.
Astute Medical takes an innovative approach to utilizing novel biomarkers of acute kidney injury and other acute conditions. Traditional biomarker discovery programs often begin with a lead-candidate biomarker. Assays are then developed and the search for a clinical application begins, often with limited success. In our approach, we first identify the unmet clinical need. Only then do we work to find the solution—the novel biomarkers that best address that need.
Clinical Opportunities for Novel Biomarkers
Through market research and collaboration with physicians, we identify clinical opportunities where novel biomarkers of acute kidney injury and other underserved disease states can make a critical difference. Our stringent process yields a detailed understanding of key clinical variables including epidemiology, patient care outcomes and economic ramifications for healthcare institutions.
To identify and target novel biomarkers relevant to the clinical need, we employ a systems biology approach, which integrates information from pathway analysis, proteomics and genomics. We tailor internally developed pilot clinical studies to include the patient population that best represents the situation the physician faces in practice, and the samples obtained in these studies permit early identification of the best-performing target biomarkers.
Using our proprietary computational analysis, we then optimize the selection of individual novel biomarkers and performance of biomarker panels. Larger multi-site validation studies are then used to confirm and extend the pilot results. Finally, we launch a test on a reliable, rapid and simple platform called the Astute140® Meter.